XETRA - Delayed Quote EUR

Newron Pharmaceuticals S.p.A. (NP5.DE)

8.03
-0.01
(-0.12%)
At close: May 23 at 5:35:45 PM GMT+2
Currency in EUR All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
51,390
51,390
9,057
6,094
5,762
Operating Expense
25,217
25,217
20,686
19,396
18,119
Operating Income
26,173
26,173
-11,629
-13,302
-12,357
Net Non Operating Interest Income Expense
-4,186
-4,186
-4,501
-4,291
-2,730
Pretax Income
21,394
21,394
-16,200
-17,472
-14,884
Tax Provision
5,551
5,551
24
21
17
Net Income Common Stockholders
15,843
15,843
-16,224
-17,493
-14,901
Diluted NI Available to Com Stockholders
15,843
15,843
-16,224
-17,493
-14,901
Basic EPS
-1.03
0.85
-0.91
-0.98
-0.84
Diluted EPS
-1.03
0.85
-0.91
-0.98
-0.84
Basic Average Shares
18,204
18,563
17,845
17,845
17,845
Diluted Average Shares
18,204
18,563
17,845
17,845
17,845
Total Operating Income as Reported
26,173
26,173
-11,629
-13,302
-12,357
Rent Expense Supplemental
64
64
98
160
115
Total Expenses
25,217
25,217
20,686
19,396
18,119
Net Income from Continuing & Discontinued Operation
15,843
15,843
-16,224
-17,493
-14,901
Normalized Income
16,211.05
16,211.05
-16,224
-17,493
-14,901
Interest Income
138
138
179
56
54
Interest Expense
4,353
4,353
4,168
3,947
2,918
Net Interest Income
-4,186
-4,186
-4,501
-4,291
-2,730
EBIT
25,747
25,747
-12,032
-13,525
-11,966
EBITDA
25,939
25,939
-11,831
-13,323
-11,757
Reconciled Depreciation
192
192
201
202
209
Net Income from Continuing Operation Net Minority Interest
15,843
15,843
-16,224
-17,493
-14,901
Total Unusual Items Excluding Goodwill
-497
-497
--
--
--
Total Unusual Items
-497
-497
--
--
--
Normalized EBITDA
26,436
26,436
-11,831
-13,323
-11,757
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-128.95
-128.95
0
0
0
12/31/2021 - 7/4/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers